Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corsair Gaming Inc (CRSR) vs Incyte Corporation (INCY) Price & Performance

Corsair Gaming IncTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Corsair Gaming Inc vs Incyte Corporation — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 16.1× Corsair Gaming Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Incyte Corporation for 33 Days on average.

CRSRINCY
Market Cap
$1.42B$22.85B
Volume
1,160,9381,927,029
Sector
TechnologyHealth
52-Week High
$14.35$129.93
52-Week Low
$4.58$83.80
Typical Hold Time
25 Days33 Days
Enterprise Value
$1.41B$18.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $13.63, up 0.29% with a bullish technical signal. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.23 exceeding expectations by 228%. Recent product launches like the VOXARA microphone and strategic acquisitions demonstrate growth initiatives. Financials show improving cash flow trends with projected 2026 operating cash flow of $106 million, though net income margins remain thin at 2.53%.

CRSR presents a mixed outlook with strong earnings momentum and product innovation offset by valuation concerns at 42x P/E. Analyst consensus is cautious with 64% hold ratings and $12.40 price target below current levels. Key risks include competitive gaming peripherals market and execution of growth strategy. The stock's near-term direction hinges on Q3 earnings delivery and sustained margin improvement.

Incyte Corporation

Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.

The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSR
100% Buy0% Sell
Avg holding period · 25 Days
INCY
100% Buy0% Sell
Avg holding period · 33 Days

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR →

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY →